Compare Tango Therapeutics Inc. (TNGX) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs US Bancorp — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while US Bancorp trades at $56.59 (market cap $87.66B). The key difference: US Bancorp is far larger — about 23.4× Tango Therapeutics Inc.'s market cap, and US Bancorp pays a 3.84% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and US Bancorp for 98 Days on average.
| TNGX | USB | |
|---|---|---|
Market Cap | $3.74B | $87.66B |
Volume | 3,438,781 | 10,545,277 |
Sector | Health | Financials |
52-Week High | $32.90 | $65.42 |
52-Week Low | $7.50 | $45.47 |
Typical Hold Time | 0 Days | 98 Days |
Enterprise Value | $2.76B | $117.17B |
Dividend Yield | — | 3.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
U.S. Bancorp (USB) trades at $56.89, down 0.92% with bearish technical signals but strong fundamentals including consistent earnings beats and a 27.61% net margin. The stock shows a P/E of 11.36 and ROE of 13.53%, with analyst consensus at Buy (51%) and a $69.94 price target. Recent news highlights dividend increases and strong Q3 expectations for net interest income and fee revenues.
Outlook remains positive based on valuation and earnings momentum, though risks include regulatory changes and interest rate sensitivity. The 3.8% dividend hike to $0.54 signals management confidence, but investors should monitor net cash flow trends and competitive pressures in regional banking.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
